Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
11:21:22 EDT Sun 21 Sep 2025
Enter Symbol
or Name
USA
CA



Q:CPRX - CATALYST PHARMACEUTICALS INC - https://www.copper-ridge.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
CPRX - Q0.419.79·19.921.819.78-0.62-3.03,558.170,03912,44220.38  20.38  19.7526.58  19.1519:40:02Aug 2815 min RT 2¢

Recent Trades - Last 10 of 12442
Time ETExPriceChangeVolume
19:40:02Q19.92-0.482
19:36:08Q20.11-0.293
19:32:55Q19.75-0.651
19:25:11Q19.92-0.4818
19:21:03Q19.81-0.591
19:17:57Q20.11-0.295
19:14:45Q19.81-0.5925
18:45:39Q19.80-0.6069
18:45:39Q19.78-0.6258
18:26:18Q19.80-0.609

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-08-28 08:03U:CPRXNews ReleaseCatalyst Pharmaceuticals to Participate in Upcoming Investor Conferences
2025-08-26 19:13U:CPRXNews ReleaseUPDATED- Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE(TM) (amifampridine) Patent Litigation with Lupin Pharmaceuticals
2025-08-25 08:03U:CPRXNews ReleaseCatalyst Pharmaceuticals Announces Settlement of FIRDAPSE(TM) (amifampridine) Patent Litigation with Lupin Pharmaceuticals
2025-08-06 16:13U:CPRXNews ReleaseCatalyst Pharmaceuticals Reports Record Second Quarter and First Half 2025 Financial Results; Provides Business Update
2025-08-06 08:03U:CPRXNews ReleaseLambert Eaton Myasthenic Syndrome (LEMS) Antibody Testing and Treatment Recommendations Added to NCCN Clinical Practice Guidelines for Small Cell Lung Cancer (SCLC)
2025-08-04 08:03U:CPRXNews ReleaseCatalyst Pharmaceuticals Appoints Daniel Curran, MD, to its Board of Directors
2025-07-22 08:03U:CPRXNews ReleaseCatalyst Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025
2025-06-02 08:03U:CPRXNews ReleaseCatalyst Pharmaceuticals Announces Appointment of William T. Andrews, MD, FACP as Chief Medical Officer
2025-05-07 16:15U:CPRXNews ReleaseCatalyst Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Provides Business Update
2025-04-30 08:03U:CPRXNews ReleaseCatalyst Pharmaceuticals to Participate in the BofA Securities Health Care Conference 2025
2025-04-22 08:03U:CPRXNews ReleaseCatalyst Pharmaceuticals to Report First Quarter 2025 Financial Results on May 7, 2025
2025-04-08 08:07U:CPRXNews ReleaseCatalyst Pharmaceuticals Announces Health Canada's Acceptance of AGAMREE(TM) New Drug Submission with Priority Review for Sub-Licensee Kye Pharmaceuticals
2025-03-04 08:03U:CPRXNews ReleaseCatalyst Pharmaceuticals to Participate in the Barclays 27th Annual Global Healthcare Conference
2025-02-26 16:13U:CPRXNews ReleaseCatalyst Pharmaceuticals Reports Record Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
2025-02-12 08:03U:CPRXNews ReleaseCatalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025
2025-01-23 08:03U:CPRXNews ReleaseCatalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2025 List of America's Most Successful Mid-Cap Companies
2025-01-21 08:19U:CPRXNews ReleaseCatalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Launched FIRDAPSE(TM) in Japan
2025-01-08 12:30U:CPRXNews ReleaseCatalyst Pharmaceuticals Announces Settlement of FIRDAPSE(TM) (amifampridine) Patent Litigation with Teva Pharmaceuticals
2024-12-16 08:03U:CPRXNews ReleaseCatalyst Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
2024-11-25 08:03U:CPRXNews ReleaseCatalyst Pharmaceuticals Recognized as One of North America's Fastest-Growing Companies on the 2024 Deloitte Technology Fast 500(TM) List